ArticleJournal of medical virology2023
Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV.
Article in Journal of medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Immunogenicity and safety of the booster COVID-19 vaccine among people with HIV: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis.Epidemiology and infection · 2023Pooled it
- Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.Journal of virology · 2025Trial
- Characteristics of humoral and T-cell immune responses in people living with HIV after breakthrough SARS-CoV-2 Omicron variant infection during December 2022 to January 2023.Virologica Sinica · 2026Article
- Humoral immunity and clinical characteristics of Chinese college students experiencing a BA.5/BF.7 and XBB.1.5 wave.Scientific reports · 2025Article
- Dynamic monitoring of antibody titers in people living with HIV during Omicron epidemic: comparison between unvaccinated and vaccinated individuals.BMC infectious diseases · 2025Article
- COVID-19 inactivated booster vaccines elicit strong protection against SARS-CoV-2 wild-type and Omicron variant in patients with breast cancer.Frontiers in medicine · 2025Article
- Dynamic SARS-CoV-2-specific B-cell and T-cell responses induced in people living with HIV after a full course of inactivated SARS-CoV-2 vaccine.Frontiers in immunology · 2025Article
- Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China.BMC infectious diseases · 2024Article
- Review
- Article
- Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers.BMC infectious diseases · 2024Observational
- Factors associated with SARS-CoV-2 infection among people living with HIV: Data from the Balearic cohort (EVHIA).PloS one · 2024Article
- Characteristics of patients with non-severe infections of different SARS-CoV-2 omicron subvariants in China.Frontiers in medicine · 2024Article
- Antibody response to inactivated COVID-19 vaccine in patients with type 2 diabetes mellitus after the booster immunization.Journal of diabetes · 2023Article
- Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis.The Journal of infection · 2023Article
- Willingness of people living with HIV to receive a second COVID-19 booster dose: a multicenter cross-sectional study in China.Frontiers in public health · 2023Article
- Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV.Journal of medical virology · 2023Article
- Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the immunogenicity to SARS-CoV-2 and evasive subvariants BA.4/5 in people living with HIV (PLWH) following a third booster shot of inactivated SARS-CoV-2 vaccine. We conducted a cross-sectional study in 318 PLWH and 241 healthy controls (HC) using SARS-CoV-2 immunoassays. Vaccine-induced immunological responses were compared before and after the third dose. Serum levels of IgG anti-RBD and inhibition rate of NAb were significantly elevated at the "post-third dose" sampling time compared with the pre-third dose in PLWH, but were relatively decreased in contrast with those of HCs. Induced humoral and cellular responses attenuated over time after triple-dose vaccination. The neutralizing capacity against BA.4/5 was also intensified but remained below the positive inhibition threshold. Seropositivity of SARS-CoV-2-specific antibodies in PLWH was prominently lower than that in HC. We also identified age, CD4 cell counts, time after the last vaccination, and WHO staging type of PLWH as independent factors associated with the seropositivity of antibodies. PLWH receiving booster shot of inactivated vaccines generate higher antibody responses than the second dose, but lower than that in HCs. Decreased anti-BA.4/5 responses than that of WT impede the protective effect of the third dose on Omicron prevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.